Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

Study of CP-675,206 in Refractory Melanoma

ClinicalTrials.gov ID: NCT00254579

Public ClinicalTrials.gov record NCT00254579. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 8:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Open Label, Single Arm Study To Evaluate The Efficacy, Safety, Tolerability And Pharmacokinetics Of CP-675,206 In Patients With Advanced Refractory And/Or Relapsed Melanoma

Study identification

NCT ID
NCT00254579
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
AstraZeneca
Industry
Enrollment
251 participants

Conditions and interventions

Interventions

  • CP-675,206 Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 30, 2005
Primary completion
Nov 30, 2009
Completion
Nov 30, 2009
Last update posted
Jun 6, 2012

2005 – 2009

United States locations

U.S. sites
36
U.S. states
20
U.S. cities
29
Facility City State ZIP Site status
Research Site Scottsdale Arizona 85260
Research Site Bentonville Arkansas 72712
Research Site Fayetteville Arkansas 72703
Research Site Little Rock Arkansas 72205
Research Site Los Angeles California 90095-6970
Research Site Los Angeles California 90095
Research Site Aurora Colorado 80045
Research Site Stamford Connecticut 06902-3628
Research Site Ocoee Florida 34761
Research Site Orlando Florida 32803
Research Site Orlando Florida 32804
Research Site Chicago Illinois 60637
Research Site Indianapolis Indiana 46202
Research Site Indianapolis Indiana 46237
Research Site Indianapolis Indiana 46260
Research Site Louisville Kentucky 40202
Research Site Baltimore Maryland 21237-3998
Research Site Boston Massachusetts 02215
Research Site Ann Arbor Michigan 48109-0946
Research Site Buffalo New York 14263
Research Site New York New York 10016
Research Site Chapel Hill North Carolina 27599-7600
Research Site Durham North Carolina 27710
Pfizer Investigational Site Columbus Ohio 43210
Research Site Columbus Ohio 43210
Research Site Bethlehem Pennsylvania 18015
Research Site Pittsburgh Pennsylvania 15232
Research Site Nashville Tennessee 37232-6307
Research Site Nashville Tennessee 37232
Research Site Salt Lake City Utah 84112
Research Site Federal Way Washington 98003
Research Site Lakewood Washington 98499
Research Site Seattle Washington 98104
Research Site Seattle Washington 98122
Research Site Tacoma Washington 98405
Research Site Madison Wisconsin 53792

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 29 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00254579, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 6, 2012 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00254579 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →